Capricor Therapeutics, Inc. (CAPR)
Market Cap | 103.99M |
Revenue (ttm) | 2.55M |
Net Income (ttm) | -29.02M |
Shares Out | 25.24M |
EPS (ttm) | -1.18 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 83,363 |
Open | 4.13 |
Previous Close | 4.19 |
Day's Range | 4.06 - 4.27 |
52-Week Range | 2.81 - 6.58 |
Beta | 4.09 |
Analysts | Buy |
Price Target | 16.83 (+308.5%) |
Earnings Date | May 9, 2023 |
About CAPR
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company al... [Read more]
Financial Performance
In 2022, CAPR's revenue was $2.55 million, an increase of 941.85% compared to the previous year's $244,898. Losses were -$29.02 million, 44.9% more than in 2021.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for CAPR stock is "Buy." The 12-month stock price forecast is $16.83, which is an increase of 308.50% from the latest price.
News

Capricor Therapeutics Presents at 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Late-Breaking Presentation Highlighted Positive18-Month Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients Late-Breaking Presentation Highlighted Positi...

Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-Enrollment Continues to Progress in HOPE-3, the Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy (DMD); Plan to Report on Interim Analysis in Q4 2023-

Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15
-Company to Host Conference Call, March 15, 2023, at 4:30 p.m. ET- -Company to Host Conference Call, March 15, 2023, at 4:30 p.m. ET-

Capricor Therapeutics Receives Clinical Research Forum's 2023 Top Ten Clinical Research Achievement Award
-HOPE-2 Trial Recognized as an Outstanding Accomplishment in Research Advancement- -HOPE-2 Trial Recognized as an Outstanding Accomplishment in Research Advancement-

Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan
-Expands Partnership with Nippon Shinyaku to Japan to Leverage Deep Experience in Drug Development for Rare Diseases and Commercial DMD Franchise-

Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients
-Statistically Significant Results in Performance of the Upper Limb PUL 2.0 (p=0.02) Extended to 18 Months, Demonstrating Long-Term Benefit in Skeletal Muscle Function-

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 Program
-Company to present 18-month data results from ongoing HOPE-2 open label extension trial of CAP-1002 in patients with Duchenne muscular dystrophy-

Capricor Announces Publication Highlighting New Advances for its Engineered Exosome Platform
-StealthX™ Exosome Platform Shows Multivalent Vaccine Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins-

Capricor (CAPR) Upgraded to Buy: What Does It Mean for the Stock?
Capricor (CAPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Capricor Therapeutics (CAPR) Reports Q3 Loss, Tops Revenue Estimates
Capricor (CAPR) delivered earnings and revenue surprises of 7.14% and 279.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Capricor Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-Enrollment Continues to Progress in HOPE-3, the Pivotal Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy-

Capricor Therapeutics to Present Third Quarter 2022 Financial Results and Recent Corporate Update on November 10
Company to Host Conference Call, November 10, 2022, at 4:30 p.m. ET Company to Host Conference Call, November 10, 2022, at 4:30 p.m. ET

Capricor Therapeutics to Present One-Year Results from HOPE-2 Open Label Extension Study at World Muscle Society 2022
SAN DIEGO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treat...

Capricor Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the trea...

Capricor Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-First Patient Treated in HOPE-3, the Pivotal Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy-

Capricor Therapeutics to Present Second Quarter 2022 Financial Results and Recent Corporate Update on August 10
Company to Host Conference Call, August 10, 2022, at 4:30 p.m. ET Company to Host Conference Call, August 10, 2022, at 4:30 p.m. ET

Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy
-Double-Blind, Randomized, Placebo-Controlled HOPE-3 Clinical Trial Designed to Enroll approximately 70 Patients-

Capricor Therapeutics Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with CAP-1002 in HOPE-2 Open Label Extension Study
-Met Primary Endpoint of Performance of the Upper Limb PUL 2.0 (p=0.02)-

Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual Conference
Results to be Presented in Late-Breaking Session Results to be Presented in Late-Breaking Session

Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer
Capricor Expands Senior Management Team to Build Commercial Strategy for Lead Asset, CAP-1002, and Further Develop Partnering Strategy for Proprietary Exosome Platform

Capricor Therapeutics to Present at the H.C. Wainwright Global Investment Conference
SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treat...

Capricor Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
-Executed Partnership with Nippon Shinyaku for the Commercialization and Distribution of CAP-1002 for Duchenne Muscular Dystrophy in the United States-

Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10
Company to Host Conference Call, May 10, 2022, at 4:30 p.m. ET Company to Host Conference Call, May 10, 2022, at 4:30 p.m. ET
7 Undervalued Penny Stocks With Major Upside
Each of these penny stocks has proven momentum throughout 2022 and major upside on top of the returns through the the first quarter. The post 7 Undervalued Penny Stocks With Major Upside appeared firs...

Capricor Therapeutics to Participate in the Cantor Fitzgerald Rare Orphan Disease Summit
SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the trea...